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21 Abstract
2 Daclatasvir is an inhibitor of hepatitis C virus NS5A protein that is used for the therapy of chronic 
3 hepatitis.  So far, published methods for analysis of daclatasvir in plasma are exclusively based on 
4 mass spectrometry, which is not always available in standard clinical laboratories.  Thus, we 
5 wished to develop and validate a simple, but still reliable and sensitive high-performance liquid 
6 chromatography (HPLC) assay with UV detection for the quantification of daclatasvir, feasible for 
7 a wide-spread clinical routine use.  The method consisted of solid-phase extraction of daclatasvir 
8 using Waters Oasis HLB 1cc cartridges, reversed-phase liquid chromatography with a Waters 
9 XTerra RP18 (150 mm × 4.6 mm, 3.5 m) column and a mobile phase of ammonium acetate 
10 buffer (pH 5.0, 10 mM) and acetonitrile (56:44, v/v), and UV detection at 318 nm.  This assay 
11 proved to be sensitive (lower limit of quantification of 0.05 g/mL), linear (correlation coefficients 
12  0.997), specific (no interference with various potentially co-administrated drugs), reproducible 
13 (both intra-day and inter-day coefficients of variation  8.9%), and accurate (deviations ranged 
14 from – 2.2 to 8.0% and from –6.5 to 9.2% for intra-day and inter-day assays, respectively).  The 
15 method was applied to therapeutic monitoring of patients undergoing daclatasvir therapy for 
16 hepatitis C and showed to be reliable and robust.  Thus, this method provides a simple, sensitive, 
17 precise, and reproducible assay for dosing daclatasvir that can be readily adaptable to routine use 
18 by clinical laboratories with standard equipment.  In addition, the stability of daclatasvir in plasma 
19 was evaluated under various conditions, including after the heating procedure required for 
20 inactivation of infectious viruses and in different light exposure conditions.  These studies 
21 evidenced photo-instability of the compound under sunlight exposure over time.  Thus, blood 
22 sampling and the whole handling procedure have to be performed quickly and with minimal light 
23 exposure.
24
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31 1.  Introduction
2 Hepatitis C virus (HCV) infection is the leading cause of progressive chronic liver disease, 
3 which can lead to the development of severe liver damages, including cirrhosis and hepatocellular 
4 carcinoma.  About 130–150 million people worldwide are chronically infected with HCV, thus 
5 resulting in a major global health problem [1].  Until 2011, the treatment options available for 
6 HCV infection were restricted to the combination of pegylated alpha interferon (PEG-INF α) with 
7 ribavirin [2].  This therapy exhibited limited efficacy, especially in patients infected with genotype 
8 1 and was associated with severe side effects [2].  The introduction of the first-generation directly 
9 acting antivirals (DAAs), telaprevir and boceprevir, in combination with PEG-INF α /RBV led to 
10 an improvement of the response rates in patients with chronic HCV genotype 1 infection.  Despite 
11 the increased efficacy of these new drugs, the association with PEG-INF α and ribavirin severely 
12 limited the tolerability of this therapy and consequently their clinical utility.  However, the recent 
13 approval of next-generation DAAs, including daclatasvir (DCV), has completely revolutionized 
14 the treatment of HCV infection by providing new highly effective IFN-free regimens for all HCV 
15 genotypes. 
16 Daclatasvir, formerly termed BMS-790052, is an inhibitor of HCV nonstructural protein 5A 
17 (NS5A) replication complex [3,4].  DCV targets NS5A with great potency, and it is thought to act 
18 on HCV by interfering with the assembly of the replication complex, more specifically inhibiting 
19 conformational change of NS5A through impairing phosphatidylinositol-4-kinase III α activation 
20 [5].  Although quite potent, resistant variants have emerged during DCV monotherapy in patients 
21 with genotype 1a and 1b [6], thus it is administered in combination therapies with sofosbuvir with 
22 or without ribavirin.
23 The increasing number of therapeutic options already available and that will be available 
24 soon for HCV-infected patients, poses a significant challenge in the choice and the management of 
25 the HCV regimen treatment, especially in case of problematic patients or in comorbidities.  In this 
26 regard, therapeutic drug monitoring (TDM) represents a very useful tool to evaluate drug efficacy 
41 and to prevent adverse events, in order to optimize the therapy.  Daclatasvir is a substrate of 
2 cytochrome P450 (CYP) enzyme 3A and an inhibitor of P-glycoprotein (P-gp), organic anion 
3 transporting polypeptide (OATP) 1B1/3, and breast cancer resistance protein (BCRP) [4].  Drug-
4 drug interactions with DCV have been observed with moderate and strong CYP 3A inducers and 
5 strong inhibitors, which significantly affect DCV concentrations [7].  As an example, dose 
6 modifications of DCV in patients treated with atazanavir or efavirenz are necessary [8].  Thus, 
7 TDM data on DCV levels can guide the clinicians to adjust the drug dosage or switch the treatment 
8 regimen, in order to guarantee the effectiveness of therapy.
9 To our knowledge, the methods published so far for DCV quantification in plasma samples 
10 are only based on liquid chromatography coupled to mass spectrometry [e.g., 9-13].  However, 
11 these methods could not be suitable for standard clinical laboratories that do not to dispose of such 
12 an equipment.  In the context of a large-scale pharmacokinetic feasibility analysis, alternative 
13 analytical methods using UV detection, which employ standard equipment and are simpler, 
14 cheaper, and easier to set up, are urgently needed. 
15 Here, we report the development and validation of the first HPLC-UV method for the 
16 measurement of DCV in human plasma.  This method was validated according to the US Food and 
17 Drug Administration (FDA) guidelines [14] and it was found to be sensitive, accurate, precise, and 
18 reproducible to meet the requirements of routine TDM laboratories.  Moreover, the stability of 
19 DCV was assessed under different common conditions to which the drug can be subjected during 
20 the sample handling and analysis in the TDM process.  In particular, this work provides, for the 
21 first time, evidences concerning the stability of DCV in plasma under the heating procedure which 
22 is required to inactive the HCV and/or HIV particles and the photodegradation of DCV when the 
23 samples were exposed at the sunlight.
24
25
26
51 2.  Material and methods
2 2.1  Chemicals and reagents
3 DCV was purchased from Alsachim (Illkirch, France).  Acetonitrile for HPLC (Gradient 
4 Grade, LiChrosolv) was from Merck (Darmstadt, Germany), methanol for chromatography was 
5 from Carlo Erba (Milan, Italy).  All other chemicals were of analytical grade and purchased from 
6 J. T. Baker (Deventer, The Netherlands).  Ultrapure water was produced by a Milli-Q water 
7 purification system (Millipore, Bedford, MA, USA).  Control human plasma (with K3EDTA as 
8 anticoagulant) was obtained from Roche (Milan, Italy; human plasma included as a negative 
9 control in the TaqScreen West Nile Virus COBAS kit).
10
11 2.2  Equipment and chromatographic conditions
12 The chromatographic system consisted of an Alliance 2695 Separation Module equipped 
13 with an online degasser and an automatic injector thermostated at 4°C, and a 2996 Photodiode 
14 Array Detector coupled with the Empower data acquisition software (version 2.0) (Waters, 
15 Milford, MA, USA).  Chromatographic separation was achieved on an XTerra RP18 (150 mm × 
16 4.6 mm, particle size 3.5 μm; Waters) analytical reversed-phase column equipped with an XTerra 
17 RP18 (20 mm × 3.9 mm, particle size 5 μm; Waters) guard column, both operating at 40°C.  The 
18 autosampler was maintained at 4°C.   The mobile phase consisted of a mixture of acetonitrile-
19 ammonium acetate buffer (pH 5.0, 10 mM) (44:56, v/v) and was filtered through a 0.22 μm nylon 
20 filter membrane (Millipore, Bedford, MA, USA) before use.  After 10 min of isocratic condition, 
21 the mobile phase was ramped to 100% acetonitrile in 1 min and maintained for 5 min to wash out 
22 any remaining plasma components.  The gradient composition was then shifted back to the starting 
23 condition in 1 min and maintained for 6 min to re-equilibrate the column.  The flow rate was 1.0 
24 mL/min, and the total assay run-time was 23 min.  Eluents were detected at a wavelength of 318 
25 nm.  As an alternative, an entirely isocratic method could be applied as well.  However, in this 
26 case a longer run-time (about 35 min) is necessary to remove all late-eluting plasma contaminants 
61 from the column.  An Extraction Manifold (Waters) liquid handling system was used to perform 
2 the sample preparation.  A DRI-BLOCK DB-3 evaporator (Techne, Stone, United Kingdom) was 
3 used for drying the SPE eluates.
4
5 2.3  Preparation of stock solutions, working solutions, calibration standards and quality control 
6 (QC) samples
7 Since possible degradation of DCV under high-intensity light conditions was previously 
8 reported [15], all solutions and samples containing DCV were protected from daylight during 
9 preparation, storage, and analysis.  Stock solutions of DCV were prepared at 1 mg/mL in 100% 
10 methanol.  The stock solution was diluted further to obtain working solutions at the concentration 
11 levels of 500, 250, 100, 50, 25, 10, 5 and 2.5 g/mL in methanol.  The stock and working solutions 
12 were stored at –20°C in the dark.  Plasma calibration standards at 10, 5, 2, 1, 0.5, 0.2, 0.1 and 0.05 
13 g/mL were freshly prepared by 1:50 dilution of the respective working solution in control human 
14 plasma and analyzed on the same day.  Of note, the total added volume of organic solvent in all 
15 samples corresponded to 2% of biological sample in accordance to the FDA guidelines [14] 
16 recommending that non-biological matrix (i.e., organic solvent) should correspond to only  2% of 
17 the volume of final biological samples.  Quality control (QC) samples at the lower limit of 
18 quantification (LLOQ = 0.05 g/mL), low (0.2 g/mL), medium (1 g/mL), high (7.5 g/mL), and 
19 the upper limit of quantification (ULOQ = 10 g/mL) concentration levels were prepared by 
20 diluting the working solutions in plasma.  The QC samples were prepared in batches at the same 
21 occasion, stored at –20°C in the dark, and then thawed and thermized at 60°C for 60 min on the 
22 day of analysis.  
23
24 2.4  Sample pretreatment and preparation 
25 Daclatasvir being sensitive to and degraded by sunlight (see Section 3.3.1), special care is 
26 required for blood sampling and for the whole handling procedure.  To this end, all manipulations 
71 have to be conducted quickly and with minimal light exposure.  Patients plasma samples were 
2 obtained after centrifugation of blood samples (5 mL), collected in tubes with K3EDTA as 
3 anticoagulant and wrapped in aluminum foil to totally protect them from light, centrifuged at 3,000 
4 rpm for 10 min at 4°C (Sigma Centrifuge, Model 2K15) and then stored at –80°C in the dark until 
5 analysis.  On the day of analysis, plasma samples were thawed and heated at 60°C for 60 min.  
6 Sample clean-up was achieved by an SPE procedure as follows.  Two hundred and fifty µL of 
7 acetonitrile were added to 250 µL of heat-inactivated plasma samples, vortexed for ~ 1 min, and 
8 then centrifuged at 13,000 rpm for 5 min at room temperature (RT) to allow the protein 
9 precipitation.  Supernatants were transferred in clean tubes and diluted with 500 µL of water.  
10 Oasis HLB 1cc cartridges (Waters, Milford, MA, USA) were pre-conditioned with 1 mL of 
11 methanol, equilibrated with 1 mL of water and then loaded with the sample mixtures.  
12 Subsequently, the cartridges were washed with 1 mL of 60% methanol (v/v).  The analytes were 
13 successively eluted with 1 mL of methanol.  The eluates were collected and evaporated to dryness 
14 under a N2 stream at 40°C (out of the light).  The dried residues were reconstituted with 62.5 L of 
15 mobile phase and centrifuged at 13,000 rpm for 5 min at RT.  The supernatants were kept at 4°C in 
16 the autosampler and 20 L of these were injected onto the HPLC system.  
17
18 2.5  Method validation
19 The validation of the assay was performed according to the guidelines for Bioanalytical 
20 Method Validation recommended by the FDA [14].  Assay validation involved the determination 
21 of recovery, linearity, selectivity, specificity, accuracy, precision, limit of detection (LOD), and 
22 LLOQ.  
23
24 2.5.1 Recovery
25 The overall recovery of DCV from human plasma was determined at the LLOQ, low-, 
26 medium-, high-QC, and ULOQ level.  The peak area response of extracted QC samples (four 
81 samples for each concentration level) was compared to that of unextracted standards obtained by 
2 injecting the corresponding concentration of DCV in mobile phase (four samples for each 
3 concentration level).  The extraction recovery was calculated as previously reported [16], using the 
4 ratio of the response and the concentration factor of the assay (250:62.5, since during the SPE 
5 procedure 250-µL plasma samples are extracted, evaporated to dryness and then reconstituted with 
6 62.5 L of mobile phase) and was expressed as a percentage of the response of the calculated 
7 amount of DCV diluted in mobile phase and directly injected onto the HPLC, which corresponds 
8 to 100% recovery.
9
10 2.5.2 Accuracy, precision, and limit of quantification
11 Intra-day and inter-day precision and accuracy values were determined by assaying plasma 
12 samples spiked with five different concentrations of DCV, corresponding to the LLOQ, low-, 
13 medium-, high-QC, and ULOQ four times on the same day and on four separate days.  Precision 
14 was expressed as a percentage of the coefficient of variation (CV), while the accuracy was 
15 expressed as the percentage of deviation between nominal and measured concentration (% bias).  
16 The criteria for acceptability of intra-day and inter-day precision and accuracy were set at ≤15% at 
17 each QC level except at LLOQ, where the values should not deviate by more than 20%, as 
18 requested by FDA guidelines [14]. 
19
20 2.5.3 Specificity and selectivity
21 In order to investigate the potential interferences from endogenous substances, ten different 
22 lots of human plasma were evaluated as blank and at LLOQ level of spiked DCV.  Chromatograms 
23 of the drug-free plasma samples were compared with the corresponding spiked plasma to check for 
24 the absence of analytic interferences from endogenous substances.  Possible interferences due to  
25 potentially co-administered drugs to the patients were also investigated by analyzing both  patient 
26 samples and blank plasma spiked with the following drugs: abacavir, acyclovir, ampicillin, 
91 amprenavir, atazanavir, carbenicillin, chloramphenicol, daptomycin, didanosine, efavirenz, 
2 erythromycin, fluconazole, foscarnet, ganciclovir, gentamicin, imipenem, indinavir, interferon, 
3 kanamycin, lamivudine, linezolid, lopinavir, nevirapine, posaconazole, ribavirin, rifampicin, 
4 ritonavir, saquinavir, simeprevir, sofosbuvir, sofosbuvir metabolite GS-331007, stavudine, 
5 streptomycin, teicoplanin, telaprevir, tenofovir, tetracycline, tigecycline, vancomycin, 
6 voriconazole, zalcitabine, and zidovudine.  
7
8 2.6.  Stability assessment
9 Stability tests were performed under different conditions simulating those to which a clinical 
10 sample may be exposed during routine analysis.  Studies of the stability of DCV in plasma 
11 included: (a) after the thermization process (60°C for 60 min), (b) after three freeze-thaw cycles; 
12 (c) storage at RT for 48 h; and (d) storage at –80°C for 5 months.  Moreover, light stability of 
13 DCV at RT for 15, 30, 60, 90, 120, 240, and 480 min was assessed in the 3 following light 
14 conditions: complete darkness (tubes wrapped in aluminum foil), minimal light exposure (with no 
15 artificial light and lit naturally through closed shutters), and sunlight exposure (to daylight at a 
16 window bench in a sunny day).  In addition, the stability of dried extracts (i.e., after SPE) at –20°C 
17 for 120 h and of extracts reconstituted in mobile phase and kept at 4°C for 96 h in the autosampler 
18 was analyzed.  For each tested condition, six series of LLOQ, low-, medium-, high-QC, and 
19 ULOQ plasma samples were prepared.  Three series were immediately analyzed, while the three 
20 remaining series were subjected to the storage or treatment conditions under examination.  The 
21 DCV concentrations in both groups of samples were compared.  For all stability studies, DCV was 
22 considered as stable if the difference between these percentages was lower than 15%, as indicated 
23 in the FDA guidelines for bioanalytical methods validation [14].
24
25
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1 3.  Results and discussion 
2 3.1  Sample preparation and chromatographic conditions
3 A good drug recovery in sample preparation is important for quantification of DCV in 
4 human plasma at low concentration levels.  Different approaches were tried such as liquid–liquid 
5 extraction with different solvents (i.e., methanol, chloroform, ethylacetate, ether, dichloromethane, 
6 and dichloroethane) and acidic precipitation techniques (e.g., precipitation with perchloric acid) 
7 for determination of DCV, but they gave low recovery or low clean-up efficiency thus resulting in 
8 significant interference from background plasma peaks (data not shown).  Deproteinization using 
9 acetonitrile followed by a simple SPE procedure employing Waters Oasis HLB 1cc cartridges was 
10 applied as a fast and reliable technique for determination of DCV in human plasma samples.  
11 Previously, a very low recovery (around 30%) following SPE of DCV from plasma was reported 
12 [9], but this result could be due to the different cartridge used for SPE (ISOLUTE C8 from 
13 International Sorbent Technology, UK) and most likely, to the fact that DCV is 99% bound to 
14 human plasma proteins [17].  For this reason, the SPE was preceded by a deproteinization step 
15 with acetonitrile.  This strategy was previously applied successfully by us to improve the 
16 extraction recovery of simeprevir, another anti-HCV drug extensively bound to plasma proteins 
17 [18].  In addition, the standard SPE procedure recommended by the producer for these cartridges 
18 was modified by introducing a washing step with 60% methanol instead of the suggested 5% 
19 concentration to improve the sample clean-up without decreasing the drug recovery.  This allowed 
20 obtaining a high and constant recovery of DCV from human plasma in all the tested concentration 
21 range (see Section 3.2.2). 
22 For the chromatographic separation of DCV, different HPLC columns, including a Waters 
23 Atlantis dC18 (150 mm × 3.9 mm, 5 m) column, a Symmetry C18 (75 mm × 4.6 mm, 3.5 m) 
24 column, and an XTerra RP18 (150 mm × 4.6 mm, 3.5 m) column, and different mobile phases 
25 were tested.  In general, better separation of DCV was observed under acidic chromatographic 
26 conditions, wherein the drug is protonated.  The best chromatographic conditions were achieved 
11
1 using an isocratic mode of acetonitrile:ammonium acetate buffer (pH 5.0, 10 mM) (44:56, v/v) at a 
2 flow rate of 1.0 ml/min on an XTerra RP18 (150 mm × 4.6 mm, 3.5 μm; Waters) column.  In these 
3 conditions, DCV eluted at 8.7 min with an optimal separation from plasma endogenous peaks (see 
4 Fig. 1).  To shorten the total run time and allow faster analysis of multiple samples, after 10 min of 
5 isocratic condition the mobile phase was ramped to 100% acetonitrile in 1 min and maintained for 
6 5 min to wash out any remaining contaminants.  Detection of DCV was performed at 318 nm, as 
7 DCV presents an absorbance maximum at this wavelength (Fig. 2) and a cleaner baseline at the 
8 retention time of DCV and a higher signal-to-noise ratio were obtained in these conditions than at 
9 different wavelengths.  Fig. 1 shows the chromatograms of (A) drug-free human plasma; (B) blank 
10 plasma spiked with DCV at LLOQ, (C) blank plasma spiked with DCV at ULOQ, and (D) plasma 
11 sample from a subject after administration of 60 mg daclatasvir.
12
13 3.2  Method validation
14 3.2.1. Linearity and sensitivity
15 An eight-point calibration standard curve of DCV in plasma, ranging from 0.05 to 10 g/mL, 
16 was prepared in triplicate in five independent runs.  The calibration curves were linear over the 
17 validated concentration range and the correlation coefficients were at least 0.997.  The LLOQ of 
18 DCV was 0.050 g/mL.  A typical chromatogram of an LLOQ sample is shown in Fig. 1B.  This 
19 LLOQ is below the Ctrough values usually observed in patients (mean level of 0.198 g/mL, ranging 
20 from 0.083 to 0.414 g/mL) [12] and thus provides sufficient sensitivity for routine analysis of 
21 human plasma samples in the clinical setting.  The LOD, defined as the concentration giving a 
22 signal-to-noise ratio of 3, was 0.020 g/mL.
23
24 3.2.2. Extraction recovery
12
1 The mean extraction recovery for DCV in the tested concentration range (0.05-10 g/mL) 
2 varied from 93.8 to 99.7%, with the CV ranging from 2.6 to 4.8%.  These results indicate that the 
3 sample extraction procedure results in clean extracts and good recovery to obtain the required 
4 sensitivity for the assay.
5
6 3.2.3. Precision and accuracy
7 The precision (expressed as % CV) and accuracy (expressed as % bias) data are reported in 
8 Table 1.  The CVs in the intraday and interday assays ranged from 2.6 to 5.5% and 3.8 to 8.9%, 
9 respectively.  The intra-day and inter-day deviations (% bias) from the nominal concentrations 
10 were always 8.0% and 9.2%, respectively.  Thus, both precision and accuracy were <15%, 
11 according to guidelines [14].  These results demonstrate that the method developed here achieves a 
12 high degree of reproducibility and accuracy.
13
14 3.2.4. Selectivity and specificity
15 The sample extraction and chromatographic analysis were developed to produce a selective 
16 assay for the analyte.  Ten different lots of commercial control human plasma were carefully 
17 evaluated for interference in the assay.  A typical chromatogram of blank plasma (Fig 1A) shows 
18 that no significant interfering peaks from human plasma were found at the retention time of DCV 
19 and at the detection wavelength of 318 nm.
20 The interference from a number of potentially co-administrated drugs (see Section 2.5.3) was 
21 investigated by determining their retention times at the concentration of 10 g/ml.  No interference 
22 was detected between the drugs tested and DCV.  Furthermore, absence of chromatographic 
23 interference was investigated during routine analysis of plasma samples from patients treated with 
24 DCV.  The absence of analytic interference was also confirmed by the use of the peak purity 
25 checking system and the library matching of the Empower software.
26
13
1 3.3  Stability data
2 3.3.1. Light stability
3 Although a European Medicines Agency (EMA)’s report stated that daclatasvir is susceptible to 
4 degradation in solution at high-intensity UV and visible light [15], to the best of our knowledge no 
5 detailed investigation on DCV photo-stability in human plasma under common light conditions 
6 that clinical samples can experience has been yet published.  Indeed, only a few data, apparently 
7 discrepant with the EMA’s report, have been published on stability of DCV in plasma following 
8 exposure to light.  In fact, recent studies reported that the drug is stable in plasma stored for 113 h 
9 under normal light condition [10] and for 24 h under ambient light (bench top) [13].  These 
10 apparent discrepancies put the photo-stability of daclatasvir in question and demanded further 
11 investigation.  The stability of DCV in plasma was tested over 8 h (T0, 15 min, 30 min, 60 min, 90 
12 min, 2 h, 4 h, and 8 h) in the 3 following light conditions: complete darkness, minimal light 
13 exposure, and sunlight exposure, and compared to those measured on fresh spiked plasmas that 
14 were immediately analyzed.  A maximum duration of 8 hours was selected to coincide with 
15 regular daily working time.  Light stability studies were performed on plasma samples spiked with 
16 DCV at the LLOQ, low-, medium-, high-QC, and ULOQ level; Fig. 3 shows the results from 
17 medium-QC samples, similar results were obtained with the other tested DCV concentrations.  
18 DCV was very stable in the complete light-free conditions up to 8 h (CV%  9.2%).  In minimal 
19 light exposure, daclatasvir was also very stable al least up to 8 h (CV%  8.9%).  In contrast, upon 
20 exposure to sunlight the drug concentration started to decrease at 90 min (reduction of 23%), and 
21 degradation reached the maximum at 4 h (reduction of 40%);  this 40% decrease in concentration 
22 then remained stable up to 8 h (CV%  7.8%).  In the next future, we plan to identify and 
23 determine the structure of the degradant(s) that are formed when plasma samples containing DCV 
24 are exposed to sunlight.  The apparent discrepancies between our data and those previously 
25 published by others on photo-stability of DCV in plasma [10,13] could be explained by the 
26 different light conditions to which plasma samples were subjected.  In fact, as we also show, 
14
1 DCV is stable upon exposure to minimal/normal daylight conditions (i.e., no direct exposure to 
2 sunlight), while is degraded when exposed to sunlight.
3
4 3.3.2. Stability under thermal virus inactivation
5 Since heat treatment (56–60°C for 30–60 min) is recommended to inactivate HCV and/or 
6 HIV particles in biological samples for safety issues [19,20], we evaluated the stability of DCV in 
7 plasma samples heated at 60°C for 60 min as previously reported [21].  As shown in Table 2, such 
8 a thermization procedure does not affect DCV concentrations within the considered concentration 
9 range.
10
11 3.3.3. Other stability studies
12 We also investigated the DCV stability in human plasma under other conditions that clinical 
13 samples commonly experience.  After three freeze–thaw cycles (24 h at -−80°C to RT) on  plasma 
14 samples spiked with DCV at 0.05, 0.2, 1, 7.5, 10 μg/mL, the concentrations of DCV were similar 
15 to those measured on fresh spiked plasmas.  Moreover, no evidence of DCV decomposition was 
16 found during short-term (48 h) storage of plasma samples at RT and long-term storage at−80°C for 
17 5 months (Table 2).  These data confirm the good stability of DCV in human plasma both at room 
18 temperature and at −80°C reported in previous studies [10-13].  In addition, the stability of DCV 
19 both in dried extracts and in processed samples reconstituted in mobile phase was assessed.  After 
20 5 days at −20°C or 4 days of storage in the autosampler at 4°C, processed samples were within  
21 15% of their nominal concentrations (Table 2), indicating that DCV is stable both in dried and in 
22 reconstituted extracts under the tested conditions.
23
24 3.4  Analysis of patient samples
25 Concentration of DCV in plasma was determined with the currently reported method in 
26 samples from patients to assess the applicability of the method.  A typical HPLC profile of a 
15
1 plasma sample obtained in a patient receiving a conventional daily oral dose of 60 mg of DCV is 
2 shown in Fig. 1D.  This plasma was obtained at steady state, just before the morning intake of the 
3 drug (Ctrough).  This method is currently used as a part of our routine TDM of DCV for both 
4 HCV-infected and HCV/HIV-coinfected patients [22].  These data confirm the clinical 
5 applicability of the present analytical method. 
6
7 4.  Conclusions
8 A simple, precise, selective, and sensitive HPLC-UV assay for the quantification of DCV in 
9 plasma has been developed and validated.  The applicability of the method and the appropriateness 
10 of the validated concentrations ranges have been demonstrated in the analysis of plasma samples 
11 of HCV-infected subjects.  So far, analytical methods developed for pharmacokinetic 
12 investigations of DCV were all based on liquid chromatography–tandem mass spectrometry 
13 methods (LC–MS/MS) and required costly MS equipment [9-13], which limited the feasibility of 
14 routine DCV analysis.  This HPLC assay with UV detection is clearly applicable to routine TDM 
15 of DCV in plasma in conventional hospital laboratories wherein LC–MS is not available.
16 Analysis of the stability of daclatasvir under different common conditions to which the drug 
17 can be subjected during routine TDM showed that DCV concentration remains stable both in 
18 plasma and in processed samples stored in various conditions as well as in samples undergoing 
19 thermal virus inactivation for 60 min at 60°C or three freeze–thaw cycles.  Noteworthy, as shown 
20 in Fig. 3, an important feature that must be kept in mind, irrespective of the analytical method, is 
21 the photo-instability of the compound upon exposure to sunlight, which requires blood sampling 
22 and the whole handling procedure to be performed quickly and with minimal light exposure. 
23 In conclusion, the present HPLC method and the results of the stability experiments could be 
24 useful for dosing DCV and properly handling DCV-containing plasma samples both in routine 
25 clinical surveys and in pharmacokinetic–pharmacodynamic study programs.
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1 Figure Legends
2
3 Fig. 1.  Representative chromatograms of (A) blank plasma sample, (B) spiked plasma sample 
4 containing DCV 0.05 g/mL (LLOQ), and (C) spiked plasma sample containing DCV 10 g/mL 
5 (ULOQ), and (D) plasma sample from a HCV/HIV co-infected patient treated with DCV in 
6 combination with sofosbuvir and ribavirin.  The measured concentration of DCV was 0.35 g/mL.
7
8 Fig. 2.  The UV spectrum of DCV.
9
10 Fig. 3.  Effect of sunlight exposure on the photo-stability of daclatasvir.  Stability results of 
11 daclatasvir in human plasma under different light conditions.  Stability of DCV in plasma was 
12 tested at different time-points in the 3 following light conditions: complete darkness, minimal light 
13 exposure, and sunlight exposure.  Details are described in the Material and methods section.  
14 Stability (%) indicates relative concentration of DCV in each test sample compared to that of 
15 freshly prepared samples as determined by HPLC analysis.  Daclatasvir is considered to be stable 
16 when the deviation of the test sample compared to the reference sample is less than 15.0%.  
17 Reported data represent the means ± SD of data derived from four experiments in triplicate.
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Table 1
Intra-day and inter-day accuracy and precision results.
_________________________________________________________________________________________________________
Nominal concentration
(g/mL)
Intra-day (n = 4) Inter-day (n = 4)
                                                                                                                 ______________________________________________________________________________________________         _________________________________________________________________________________________________
Mean measured 
concentration 
(g/mL)
Accuracya
(% bias)
Precision
(% CV)
Mean measured 
concentration 
(g/mL)
Accuracy
(% bias)
Precision
(% CV)
____________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________
      0.05 (LLOQ) 0.054 8.0 5.5 0.047 -6.0 8.9
      0.2 (low QC) 0.207 3.5 4.1 0.187 -6.5 6.4
      1.0 (medium QC) 0.978 -2.2 2.6 1.092 9.2 7.1
      7.5 (high QC) 7.577 1.0 3.8 7.329 -2.3 3.8
      10.0 (ULOQ) 9.786 -2.1 4.8 10.371 3.7 5.9
____________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________
aAccuracy = [(measured concentration – nominal concentration)/nominal concentration] x 100
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Table 2
Stability of DCV in plasma samples and in dried or reconstituted extracts under different treatment/storage conditions.
                                                                                                          Nominal concentration (g/mL)
0.05 0.2 1.0 7.5 10.0
(A) In plasma heated at 60°C for 60 min
Mean measured conc. at t=0 (g/mL) 0.055 0.187 1.109 7.678 9.877
Mean recovered conc. (g/mL) 0.052 0.210 1.112 7.499 9.688
Deviation (%) -5.4 12.3 0.3 -2.3 -1.9
CV (%) 6.8 4.3 5.3 1.9 2.1
(B) In plasma subjected to three freeze/thaw cycles
Mean measured conc. at t=0 (g/mL) 0.048 0.211 1.006 7.655 10.333
Mean recovered conc. (g/mL) 0.053 0.188 1.100 7.621 10.446
Deviation (%) 10.4 -10.9 9.3 -0.4 1.1
CV (%) 6.7 8.1 6.3 1.4 0.9
(C) In plasma stored at room temperature for 48 h
Mean measured conc. at t=0 (g/mL) 0.044 0.212 1.040 7.488 11.016
22
Mean recovered conc. (g/mL) 0.048 0.208 1.089 7.611 10.566
Deviation (%) 9.1 -1.9 4.7 1.6 -4.1
CV (%) 5.5 6.3 2.6 5.2 2.3
(D) In plasma stored at – 80°C for five months
Mean measured conc. at t=0 (g/mL) 0.059 0.219 0.966 7.596 9.866
Mean recovered conc. (g/mL) 0.055 0.211 0.988 7.623 9.542
Deviation (%) -6.8 -3.7 2.3 0.4 -3.3
CV (%) 8.5 6.2 2.4 1.8 4.1
(E) In dried extracts stored at – 20°C for 120 h
Mean measured conc. at t=0 (g/mL) 0.048 0.198 1.010 7.455 10.242
Mean recovered conc. (g/mL) 0.051 0.203 0.999 7.388 10.983
Deviation (%) 6.3 2.5 -1.1 -0.9 7.2
CV (%) 7.6 1.6 0.9 3.3 2.2
(F) In reconstituted extracts stored at 4°C for 96 h
Mean measured conc. at t=0 (g/mL) 0.059 0.220 0.933 7.711 9.653
Mean recovered conc. (g/mL) 0.063 0.208 0.974 7.622 9.833
Deviation (%) 6.8 -5.5 4.4 -1.2 1.9
CV (%) 9.5 6.2 0.8 1.5 2.1
23
Figure 1
A B
C D
DCV
DCV
DCV
Figure 2
Figure 3
Highlights
• The first HPLC-UV method was developed for the determination of DCV in human plasma.
• This method was applied to quantification of daclatasvir in clinical samples.
• Daclatasvir is degraded by sunlight.
